Cara Therapeutics Inc - ESG Rating & Company Profile powered by AI
This SDG rating for Cara Therapeutics Inc indicates its transparency towards the UN SDGs. The assessment of Cara Therapeutics Inc uses intelligence from across the web and also from public filings by Cara Therapeutics Inc. The webpage contains a free E,S&G assessment for Cara Therapeutics Inc.
Cara Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 3.2, social score of 6.4 and governance score of 6.7.
5.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 808 | Tilray Inc | 5.6 | High |
| 808 | Y-mAbs Therapeutics Inc | 5.6 | High |
| 835 | Cara Therapeutics Inc | 5.5 | High |
| 835 | Animalcare Group PLC | 5.5 | High |
| 835 | Bafna Pharmaceuticals Ltd | 5.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Cara Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Cara Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Cara Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Cara Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Cara Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Cara Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Cara Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Cara Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Cara Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Cara Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Cara Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Cara Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Cara Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Cara Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Cara Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Cara Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Cara Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Cara Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.